ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,464.62
-0.16%
Dow Jones
39,150.33
0.04%
US Dollar vs MXN
18.1108
0.00%
Brent Oil
84.39
0.00%
Bitcoin
64,431.54
0.29%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Cyclacel Pharmaceuticals Inc (CYCCP)

  7. Cyclacel Pharmaceuticals Inc (CYCCP) Noticias

CYCCP

Cyclacel Pharmaceuticals (CYCCP)

Cyclacel Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CYCCP
FechaHoraFuenteTítuloSímboloCompañía
04/06/202407:00GlobeNewswire Inc.Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
03/06/202407:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
17/05/202408:56Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202416:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202415:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/05/202415:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business UpdateNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
13/05/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
13/05/202415:05Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
08/05/202408:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
07/05/202420:56Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
07/05/202420:53Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
07/05/202420:52Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
06/05/202416:26Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
02/05/202415:30GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/04/202412:51AllPennyStocks.com$8 Million Private Placement Announcement Sends Biotech FlyingNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/04/202406:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
01/04/202408:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for CancerNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
19/03/202415:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
13/03/202415:05GlobeNewswire Inc.Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
07/03/202408:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
06/03/202408:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
20/02/202408:15GlobeNewswire Inc.Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
14/02/202415:31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
31/01/202415:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/01/202408:15GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical OfficerNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
10/01/202412:35Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
26/12/202308:28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CYCCPCyclacel Pharmaceuticals Inc
18/12/202308:00GlobeNewswire Inc.Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP DeletionsNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
12/12/202315:05GlobeNewswire Inc.Cyclacel Pharmaceuticals Announces Reverse Stock SplitNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
30/11/202308:15GlobeNewswire Inc.Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SECNASDAQ:CYCCPCyclacel Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CYCCP

Su Consulta Reciente

EU
SDG
Synergie
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados